Formulation comprising cannabinoids

Abstract

The present invention relates to specific types of pharmaceutical formulations and compositions comprising cannabinoids for use in the treatment of various disorders.

1 . A combination comprising Tetrahydrocannabinol (THC) and Cannabidiol (CBD) for use in the treatment of a disorder selected from the list comprising: pain, blisters, neurodegenerative disorders or post-traumatic stress syndrome; wherein said combination is formulated in a transdermal patch,
 characterized in that said transdermal patch comprises at least one transdermal nanofibrous electrospun film.   
     
     
         2 . The combination for use according to  claim 1 , wherein said film comprises nano-encapsulated THC and/or CBD. 
     
     
         3 . The combination for use according to anyone of  claim 1  or  2 , wherein at least one of said THC and CBD is a prodrug. 
     
     
         4 . The combination for use according to anyone of  claims 1  to  3 , wherein said transdermal patch is selected from the list comprising: reservoir patch, matrix patch, vapor patch or drug-in-adhesive patch. 
     
     
         5 . The combination for use according to  claim 4 , wherein said drug-in-adhesive patch is selected from the list comprising: single-layer drug-in-adhesive patch or multi-layer drug-in-adhesive patch. 
     
     
         6 . The combination for use according to anyone of  claims 1  to  5 , wherein said transdermal patch and/or film further comprises at least one polymer. 
     
     
         7 . The combination for use according to  claim 6 , wherein said polymer is polyethylene oxide. 
     
     
         8 . The combination for use according to anyone of  claims 1  to  7 , wherein said transdermal patch and/or film further comprises a skin penetration enhancer. 
     
     
         9 . The combination for use according to anyone of  claims 1  to  8 , wherein said transdermal patch and/or film further comprises an antioxidant. 
     
     
         10 . The combination for use according to anyone of  claims 1  to  9 , wherein said blisters are caused by burns or other related traumas or a disorder selected from the list comprising:
 skin allergies, different forms of eczema, bullous pemphigoid, bullous impetigo, dermatitis herpetiformis, pemphigus vulgaris, mucous membrane pemphigoid, pemphigoid gestationis, epidermolysis bullosa, pemphigus foliaceous or toxic epidermal necrolysis. 
 
     
     
         11 . The combination for use according to anyone of  claims 1  to  10 , wherein said neurodegenerative disorder is selected from the list comprising: Alzheimer's disease (AD) and other dementias, Parkinson's disease (PD) and PD-related disorders, Essential Tremor, Multiple System Atrophy, Huntington's disease or Motor Neuron Diseases (MND). 
     
     
         12 . The combination for use according to anyone of  claims 1  to  11 , wherein said use includes the alleviation of secondary symptoms caused by said disorders. 
     
     
         13 . The combination for use according to  claim 12  wherein said secondary symptoms are selected from the list comprising, secondary pain, itch, secondary impetigos, swelling, inflammation or bacterial infection. 
     
     
         14 . The combination for use according to anyone of  claims 1  to  13 , wherein said use includes the reduction of opioid consumption/dependency in the treatment of at least one of said disorders. 
     
     
         15 . The combination for use according to anyone of  claims 1  to  14 , further comprising one or more additional pharmaceutically active agents suitable for use in the treatment of said disorders.